Table 2 Cox regression models of overall survival as a function of either N stage or lymph node ratio (LNR) and other established predictors of worse prognosis (N = 211 patients with stage III colorectal adenocarcinoma)
Predictors | Model with N stage | Model with LNR (10%) | Model with LNR (16%) | |||
|---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
N stage | 0.044 | NA | NA | |||
N1 | Reference | NA | NA | |||
N2 | 2.02 (1.02–4.00) | NA | NA | |||
LNR (10%) | NA | 0.010 | NA | |||
< 10 | NA | Reference | NA | |||
≥ 10 | NA | 2.76 (1.28–5.96) | NA | |||
LNR (16%) | NA | NA | 0.001 | |||
< 16 | NA | NA | Reference | |||
≥ 16 | NA | NA | 3.70 (1.86–7.36) | |||
Age | 1.03 (1.00–1.05) | 0.066 | 1.02 (1.00–1.05) | 0.074 | 1.03 (1.00–1.05) | 0.058 |
Sex | 0.25 | 0.21 | 0.27 | |||
Female | Reference | Reference | Reference | |||
Male | 1.52 (0.75–3.09) | 1.57 (0.77–3.18) | 1.49 (0.73–3.01) | |||
Tumor site | 0.035 | 0.014 | 0.026 | |||
Rectum | Reference | Reference | Reference | |||
Colon | 3.17 (1.08–9.30) | 4.1 (1.3–12.9) | 3.66 (1.17–11.4) | |||
Neoadjuvant therapy | 0.012 | 0.010 | 0.011 | |||
No neoadjuvant therapy | Reference | Reference | Reference | |||
Chemotherapy and/or radiotherapy | 4.1 (1.4–12.2) | 4.6 (1.4–14.9) | 4.49 (1.40–14.3) | |||
Grade | 0.026 | 0.016 | 0.028 | |||
Well-differentiated or moderately differentiated | Reference | Reference | Reference | |||
Poorly differentiated | 2.77 (1.36–6.76) | 3.02 (1.23–7.40) | 2.67 (1.11–6.41) | |||
Histologic subtype | 0.089 | 0.091 | 0.090 | |||
Classic | Reference | Reference | Reference | |||
Mucinous | 0.43 (0.16–1.14) | 0.44 (0.17–1.14) | 0.44 (0.17–1.14) | |||